Laboratory Medicine and Nosocomial Infections: How Norway Reduces MRSA
|
By LabMedica International staff writers Posted on 18 Feb 2010 |
Norwegian hospitals have had considerable success in their anti-methicillin-resistant Staphylococcus aureus (MRSA) efforts.
The country introduced strict control on antibiotic use that resulted in far fewer cases of the MRSA infections. An estimated 19,000 patients in U.S. hospitals died each year following MRSA infection, and observers are suggesting that the U.S. healthcare system could reduce those cases by replicating the Scandinavian country's control program.
How does Norway do it? Norwegian doctors prescribe fewer antibiotics than any other country, so people do not have a chance to develop resistance to them. Patients with MRSA are isolated and medical staff members who test positive stay at home. Doctors track each case of MRSA by its individual strain, interviewing patients about where they have been and who they have been with testing anyone who has been in contact with them.
"It's a very sad situation that in some places so many are dying from this, because we have shown here in Norway that methicillin-resistant Staphylococcus aureus can be controlled, and with not too much effort," said Jan Hendrik-Binder, Oslo's MRSA medical adviser. "But you have to take it seriously, you have to give it attention, and you must not give up."
Now a spate of new studies from around the world proves that Norway's model can be replicated with extraordinary success, and public health experts are saying deaths from MRSA are unnecessary.
In a small public hospital called the Queen Elizabeth Hospital Kings Lynn, NHS Trust (UK), about 100 miles outside of London (UK) microbiologist Prof. Lynne Liebowitz noticed the low Nordic MRSA rates, while the numbers in her hospital were increasing.
Prof. Liebowitz asked doctors to stop almost completely using two groups of antibiotics (fluoroquinolones and/or cephalosporins) known for provoking MRSA infections. One month later, MRSA rates were tumbling. In 2003, when the study started the hospital had 47 MRSA bloodstream infections. In 2008, they had one. This has been replicated at four other hospitals, all with the same results.
Related Links:
Queen Elizabeth Hospital Kings Lynn
The country introduced strict control on antibiotic use that resulted in far fewer cases of the MRSA infections. An estimated 19,000 patients in U.S. hospitals died each year following MRSA infection, and observers are suggesting that the U.S. healthcare system could reduce those cases by replicating the Scandinavian country's control program.
How does Norway do it? Norwegian doctors prescribe fewer antibiotics than any other country, so people do not have a chance to develop resistance to them. Patients with MRSA are isolated and medical staff members who test positive stay at home. Doctors track each case of MRSA by its individual strain, interviewing patients about where they have been and who they have been with testing anyone who has been in contact with them.
"It's a very sad situation that in some places so many are dying from this, because we have shown here in Norway that methicillin-resistant Staphylococcus aureus can be controlled, and with not too much effort," said Jan Hendrik-Binder, Oslo's MRSA medical adviser. "But you have to take it seriously, you have to give it attention, and you must not give up."
Now a spate of new studies from around the world proves that Norway's model can be replicated with extraordinary success, and public health experts are saying deaths from MRSA are unnecessary.
In a small public hospital called the Queen Elizabeth Hospital Kings Lynn, NHS Trust (UK), about 100 miles outside of London (UK) microbiologist Prof. Lynne Liebowitz noticed the low Nordic MRSA rates, while the numbers in her hospital were increasing.
Prof. Liebowitz asked doctors to stop almost completely using two groups of antibiotics (fluoroquinolones and/or cephalosporins) known for provoking MRSA infections. One month later, MRSA rates were tumbling. In 2003, when the study started the hospital had 47 MRSA bloodstream infections. In 2008, they had one. This has been replicated at four other hospitals, all with the same results.
Related Links:
Queen Elizabeth Hospital Kings Lynn
Latest Microbiology News
- Automated Blood Culture System Speeds Detection of Bloodstream Infections
- New Culture Medium Speeds C. difficile Resistance Detection and Reduces Costs
- Gut Microbiome Signatures Help Identify Risk of IBD Progression
- FDA-Cleared Gastrointestinal Panel Detects 24 Pathogen Targets
- New AMR Assay Supports Rapid Infection Control Screening in Hospitals
- Diagnostic Gaps Complicate Bundibugyo Ebola Outbreak Response in Congo
- Study Finds Hidden Mpox Infections May Drive Ongoing Spread
- Large-Scale Genomic Surveillance Tracks Resistant Bacteria Across European Hospitals
- Molecular Urine and Stool Tests Do Not Improve Early TB Treatment in Hospitalized HIV Patients
- Rapid Antigen Biosensor Detects Active Tuberculosis in One Hour
- Label-Free Microscopy Method Enables Faster, Quantitative Detection of Malaria
- Oral–Gut Microbiome Signatures Identify Early Gastric Cancer
- Gut Microbiome Test Predicts Melanoma Recurrence After Surgery
- Rapid Blood-Culture Susceptibility Panel Expands Coverage for Gram-Negative Infections
- Antibiotic Resistance Genes Found in Newborns Within Hours of Birth
- Rapid Color Test Stratifies Virulent and Resistant Staph Strains
Channels
Clinical Chemistry
view channel
Saliva-Based Test Detects Biochemical Signs of Sleep Loss
Acute sleep loss impairs cognition and motor skills, raising safety risks that resemble alcohol intoxication. Clinicians currently lack an objective biochemical test to determine when someone is dangerously... Read more
Simple Dual-Tau Blood Test Detects and Stages Alzheimer’s Disease
Alzheimer’s disease is typically confirmed and staged with positron emission tomography scans and cerebrospinal fluid testing, procedures that are costly and invasive. Broader access to minimally invasive... Read more
Alzheimer’s Blood Biomarkers Linked to Early Cognitive Differences Before Dementia
Blood-based screening for Alzheimer’s disease offers a noninvasive, lower-cost alternative to brain imaging or spinal fluid testing, yet its ability to flag the earliest cognitive changes has been unclear.... Read moreMolecular Diagnostics
view channel
New PCR Assay Supports Bundibugyo Ebola Outbreak Surveillance
Rapid identification of Ebola infections is essential to limit transmission and guide public health response, yet detection can be difficult when outbreaks involve rare variants. The current outbreaks... Read more
Plasma Protein Signature Predicts Lung Cancer Risk Up to Five Years Ahead
Lung cancer remains a leading cause of cancer death, and many cases are detected only after symptoms appear. Current screening programs largely target people with a history of smoking, leaving other at-risk... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channelAptamer-Based Biosensor Enables Mutation-Resilient SARS-CoV-2 Detection
Rapid evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can undermine existing molecular diagnostics, especially when assays target small viral components. Double-antibody sandwich... Read more
Study Points to Autoimmune Pathway Behind Long COVID Symptoms
Long COVID leaves many SARS-CoV-2 survivors with persistent fatigue, cognitive issues, palpitations, and musculoskeletal pain for months or years. Estimates cited in new research suggest 4%–20% of infected... Read more
Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read morePathology
view channel
3D Spatial Multi-Omics Maps Intra-Tumor Diversity in Colorectal Cancer
Colorectal cancer remains a leading cause of cancer death, and clinical decision-making is complicated by marked intra-tumor heterogeneity. Conventional bulk sequencing averages molecular signals across... Read more
Blood-Based Method Tracks Gene Activity in the Living Brain
Real-time measurement of gene activity in the brain has been limited by assays requiring destructive tissue sampling. Tracking active genes could reveal how the body responds to environmental factors,... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read moreIndustry
view channel
Collaboration Advances ctDNA-Guided Development in Metastatic Colorectal Cancer
Natera, Inc. (Austin, TX, USA) and CytoDyn Inc. (Vancouver, WA, USA) announced a strategic collaboration focused on metastatic colorectal cancer (mCRC). Under the agreement, Natera will evaluate circulating... Read more








